Intrathecal chemotherapy in lymphomatous meningitis

Fabio Canova, Dario Marino, Chiara Trentin, Caterina Soldà, Cristina Ghiotto, Savina Maria Luciana Aversa

Research output: Contribution to journalArticle


Central Nervous System (CNS) involvement in lymphoma can occur whether at diagnosis or, more often, at the progression or recurrence of disease and the most frequent clinical manifestation is lymphomatous meningitis (LM). The first risk factor for LM development is the histotype, with the highest incidence for highly aggressive non-Hodgkin's lymphomas (NHL) such as Burkitt's lymphoma (BL) and lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL) and the lowest for indolent NHL. LM prophylaxis in aggressive NHL (other than BL and LBL/ALL) is a much debated question, because the identification of specific risk factors remains controversial. Moreover, there is not a consensus if the LM prophylaxis should consist of systemic chemotherapy (CT), intrathecal (i.t.) CT or both. In case of LM, the i.t. CT has a key role, but there is not a consensus on treatment schedule. Newer intensified regimens and rituximab lead to reconsider the whole approach to LM.

Original languageEnglish
Pages (from-to)127-134
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Issue number2
Publication statusPublished - Aug 2011


  • Central nervous system
  • Hodgkin
  • Intrathecal
  • Lymphoma
  • Lymphomatous meningitis
  • Meningeal

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Intrathecal chemotherapy in lymphomatous meningitis'. Together they form a unique fingerprint.

  • Cite this